Gene · 2213
Papers4,232
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
261 to 280 of 4,232
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Immunopathogenesis of Type 1 and Type 2 Leprosy Reaction: An Update Review. | Cureus | 2023 | 38130570 | PubTator, text mining | PubMed |
| A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC. | Oncoimmunology | 2023 | 38126034 | PubTator, text mining | PubMed |
| The correlates of neonatal complement component 3 and 4 protein concentrations with a focus on psychiatric and autoimmune disorders. | Cell Genom | 2023 | 38116117 | PubTator, text mining | PubMed |
| Correction: C-reactive protein impairs immune response of CD8+ T cells via FcγRIIb-p38MAPK-ROS axis in multiple myeloma. | J Immunother Cancer | 2023 | 38101865 | PubTator, text mining | PubMed |
| Broadening the horizon: potential applications of CAR-T cells beyond current indications. | Front Immunol | 2023 | 38090582 | PubTator, text mining | PubMed |
| Advancing CAR-based immunotherapies in solid tumors: CAR- macrophages and neutrophils. | Front Immunol | 2023 | 38090576 | PubTator, text mining | PubMed |
| Distinct effector functions mediated by Fc regions of bovine IgG subclasses and their interaction with Fc gamma receptors. | Front Immunol | 2023 | 38077405 | PubTator, text mining | PubMed |
| Lipopolysaccharide Impedes Bone Repair in FcγRIIB-Deficient Mice. | Int J Mol Sci | 2023 | 38069267 | PubTator, text mining | PubMed |
| Immunomodulation of Antibody Glycosylation through the Placental Transfer. | Int J Mol Sci | 2023 | 38069094 | PubTator, text mining | PubMed |
| Comprehensive Profiling and Therapeutic Insights into Differentially Expressed Genes in Hepatocellular Carcinoma. | Cancers (Basel) | 2023 | 38067357 | PubTator, text mining | PubMed |
| Dual blockade of CD47 and CD24 signaling using a novel bispecific antibody fusion protein enhances macrophage immunotherapy. | Mol Ther Oncolytics | 2023 | 38046893 | PubTator, text mining | PubMed |
| Impact of SARS-CoV-2 vaccination on FcγRIIIA/CD16 dynamics in Natural Killer cells: relevance for antibody-dependent functions. | Front Immunol | 2023 | 38045702 | PubTator, text mining | PubMed |
| Intranasal immunization with an RBD-hemagglutinin fusion protein harnesses preexisting immunity to enhance antigen-specific responses. | J Clin Invest | 2023 | 38038133 | PubTator, text mining | PubMed |
| The spectrum of B cells in the pathogenesis, diagnosis and therapeutic applications of immunoglobulin G4-related disease. | Clin Transl Immunology | 2023 | 38034079 | PubTator, text mining | PubMed |
| Integrated Analysis of Ferroptosis and Immunity-Related Genes Associated with Diabetic Kidney Disease. | Diabetes Metab Syndr Obes | 2023 | 38028994 | PubTator, text mining | PubMed |
| SHIP1 therapeutic target enablement: Identification and evaluation of inhibitors for the treatment of late-onset Alzheimer's disease. | Alzheimers Dement (N Y) | 2023 | 38023622 | PubTator, text mining | PubMed |
| Expression of Bruton´s tyrosine kinase in different type of brain lesions of multiple sclerosis patients and during experimental demyelination. | Front Immunol | 2023 | 38022591 | PubTator, text mining | PubMed |
| Nonfucosylation of an anti-TIGIT antibody enhances FcγR engagement, driving innate immune activation and antitumor activity. | Front Immunol | 2023 | 38022590 | PubTator, text mining | PubMed |
| Blood-derived product therapies for SARS-CoV-2 infection and long COVID. | MedComm (2020) | 2023 | 38020714 | PubTator, text mining | PubMed |
| Impact of Fc receptors and host characteristics on myeloid phagocytic response to rituximab-treated 3D-cultured B-cell lymphoma. | Immunother Adv | 2023 | 38020313 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2213/papers?page=14